Revealing Melatonin’s Mysteries: Receptors, Signaling Pathways, and Therapeutics Applications

Abstract

Melatonin (5-methoxy-acetyl tryptamine) is a sleep-inducing hormone, and the pineal gland produces it in response to the circadian clock of darkness. In the body, MT1 and MT2 receptors are mostly found, having an orthosteric pocket and ligand binding determinants. Melatonin acts by binding on melatonin receptors, intracellular proteins, and orphan nuclear receptors. It inhibits adenyl cyclase and activates phospholipase C, resulting in gene expression and an intracellular alteration environment. Melatonin signaling pathways are also associated with other intracellular signaling pathways, i. e., cAMP/PKA and MAPK/ERK pathways. Relative expression of different proteins depends on the coupling profile of G protein, accounting pharmacology of the melatonin receptor bias system, and mediates action in a Gi-dependent manner. It shows antioxidant, antitumor, antiproliferative, and neuroprotective activity. Different types of melatonin agonists have been synthesized for the treatment of sleeping disorders. Researchers have developed therapeutics that target melatonin signaling, which could benefit a wide range of medical conditions. This review focuses on melatonin receptors, pharmacology, and signaling cascades; it aims to provide basic mechanical aspects of the receptor’s pharmacology, melatonin’s functions in cancer and neurodegenerative diseases, and any treatments and drugs designed for these diseases. This will allow a basic comparison between the receptors in question, highlighting any parallels and differences that may exist and providing fundamental knowledge about these receptors to future researchers.

Keywords

melatonin - receptor structure - receptor signaling cascade - pineal gland

Publication History

Received: 04 August 2023

Accepted after revision: 11 December 2023

Accepted Manuscript online:
11 December 2023

Article published online:
19 February 2024

• References

• 1 do Amaral FG, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. Arch Endocrinol Metab 2018; 62: 472-479
• 2 Ruan W, Yuan X, Eltzschig HK. Circadian rhythm as a therapeutic target. Nat Rev Drug Discov 2021; 20: 287-307
• 3 Radogna F, Albertini MC, De Nicola M. et al. Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid. Mitochondrion 2015; 21: 113-121
• 4 Nikolaev G, Robeva R, Konakchieva R. Membrane melatonin receptors activated cell signaling in physiology and disease. Int J Mol Sci 2021; 23: 471
• 5 Bach V, Delanaud S, Barcat L. et al. Distal skin vasodilation in sleep preparedness, and its impact on thermal status in preterm neonates. Sleep Med 2019; 60: 26-30
• 6 Li D, Smith D, Hardeland R. et al. Melatonin receptor genes in vertebrates. Int J Mol Sci 2013; 14: 11208-11223
• 7 Sheng W, Jin M, Pan G. et al. Cellular localization of melatonin receptor Mel1b in pigeon retina. Neuropeptides 2019; 78: 101974
• 8 Dubocovich ML, Delagrange P, Krause DN. et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010; 62: 343-380
• 9 Gombert M, Codoñer-Franch P. Melatonin in early nutrition: long-term effects on cardiovascular system. Int J Mol Sci 2021; 22: 6809
• 10 Tan D-X, Manchester L, Esteban-Zubero E. et al. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules 2015; 20: 18886-18906
• 11 Basler M, Jetter A, Fink D. et al. Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature. Breast Care 2014; 9: 182-187
• 12 Jockers R, Delagrange P, Dubocovich ML. et al. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol 2016; 173: 2702-2725
• 13 Argueta J, Solís-Chagoyán H, Estrada-Reyes R. et al. Further evidence of the melatonin calmodulin interaction: effect on CaMKII activity. Int J Mol Sci 2022; 23: 2479
• 14 Ma N, Zhang J, Reiter RJ, Ma X. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation. Med Res Rev 2020; 40: 606-632
• 15 Tan D-X, Manchester L, Qin L, Reiter R. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. Int J Mol Sci 2016; 17: 2124
• 16 Li DY, Smith DG, Hardeland R. et al. Melatonin receptor genes in vertebrates. Int J Mol Sci 2013; 14: 11208-11223
• 17 López-Canul M, Comai S, Domínguez-López S. et al. Antinociceptive properties of selective MT2 melatonin receptor partial agonists. Eur J Pharmacol 2015; 764: 424-432
• 18 Emet M, Ozcan H, Ozel L. et al. A review of melatonin, its receptors and drugs. Eurasian J Med 2016; 48: 135
• 19 Imbesi M, Arslan AD, Yildiz S. et al. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal ‘clock’ gene expression in striatal neurons in vitro. J Pineal Res 2009; 46: 87-94
• 20 Wood S, Loudon A. Clocks for all seasons: unwinding the roles and mechanisms of circadian and interval timers in the hypothalamus and pituitary. J Endocrinol 2014; 222: R39
• 21 Pandiperumal S, Trakht I, Srinivasan V. et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-353
• 22 Liu D, Wei N, Man H-Y. et al. The MT2 receptor stimulates axonogenesis and enhances synaptic transmission by activating Akt signaling. Cell Death Differ 2015; 22: 583-596
• 23 Hazlerigg D, Loudon A. New insights into ancient seasonal life timers. Curr Biol 2008; 18: R795-R804
• 24 Johansson LC, Stauch B, McCorvy JD. et al. XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity. Nature 2019; 569: 289-292
• 25 Stauch B, Johansson LC, McCorvy JD. et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. Nature 2019; 569: 284-288
• 26 Pala D, Lodola A, Bedini A. et al. Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci 2013; 14: 8093-8121
• 27 Chan KH, Tse LH, Huang X, Wong YH. Molecular basis defining the selectivity of substituted isoquinolinones for the melatonin MT2 receptor. Biochem Pharmacol 2020; 177: 114020
• 28 Bourin M. Physiology and pharmacology of melatonin. In: Gargiulo PÁ, Mesones Arroyo HL (eds). Psychiatry and neuroscience update. Springer International Publishing; Cham: 2021: 261-277
• 29 Zlotos DariusP, Jockers R, Cecon E. et al. MT₁ and MT₂ Melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem 2014; 57: 3161-3185
• 30 Nishiyama K, Hirai K. The melatonin agonist ramelteon induces duration-dependent clock gene expression through cAMP signaling in pancreatic INS-1 β-cells. PLoS One 2014; 9: e102073
• 31 Peschke E, Bähr I, Mühlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. J Pineal Res 2015; 59: 1-23
• 32 Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. Br J Pharmacol 2018; 175: 3263-3280
• 33 Carbajo-Pescador S, García-Palomo A, Martín-Renedo J. et al. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor: Melatonin receptors in human hepatocarcinoma cells. J Pineal Res 2011; 51: 463-471
• 34 Saikia S, Bordoloi M, Sarmah R. Established and in-trial GPCR families in clinical trials: a review for target selection. Curr Drug Targets 2019; 20: 522-539
• 35 Bähr I, Mühlbauer E, Albrecht E, Peschke E. Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the Gαq protein-coupled and PI3K signaling pathways: Melatonin receptor and glucagon secretion. J Pineal Res 2012; 53: 390-398
• 36 Lee S-J, Jung YH, Oh SY. et al. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with Gαq in skin wound healing. J Pineal Res 2014; 57: 393-407
• 37 Borges R, Johnson WE, O’Brien SJ. et al. The role of gene duplication and unconstrained selective pressures in the melanopsin gene family evolution and vertebrate circadian rhythm regulation. PLoS One 2012; 7: e52413
• 38 Cecon E, Boutin JA, Jockers R. Molecular characterization and pharmacology of melatonin receptors in animals. Receptors 2023; 2: 127-147
• 39 Valenzuela-Melgarejo FJ, Lagunas C, Carmona-Pastén F. et al. Supraphysiological role of melatonin over vascular dysfunction of pregnancy, a new therapeutic agent?. Front Physiol 2021; 12: 767684
• 40 Dortch-Carnes J, Tosini G. Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells. Exp Eye Res 2013; 107: 1-10
• 41 Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol 2019; 15: 105-125
• 42 Lee S-J, Jung YH, Oh SY. et al. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with Gαq in skin wound healing. J Pineal Res 2014; 57: 393-407
• 43 Pfeffer M, Rauch A, Korf H-W, Von Gall C. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors. Chronobiol Int 2012; 29: 415-429
• 44 Zhang Y, Li H, Pu Y. et al. Melatonin-mediated inhibition of Purkinje neuron P-type Ca ²⁺channels in vitro induces neuronal hyperexcitability through the phosphatidylinositol 3-kinase-dependent protein kinase C delta pathway. J Pineal Res 2015; 58: 321-334
• 45 Owino S, Sánchez-Bretaño A, Tchio C. et al. Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI 3K activity. J Pineal Res 2018; 64: e12462
• 46 West A, Dupré SM, Yu L. et al. Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis. Mol Endocrinol 2013; 27: 979-989
• 47 Vriend J, Reiter RJ. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res 2015; 58: 1-11
• 48 Wiechmann AF, Sherry DM. Role of melatonin and its receptors in the vertebrate retina. Int Rev Cell Mol Biol 2013; 300: 211-242
• 49 Hiragaki S, Baba K, Coulson E. et al. Melatonin signaling modulates clock genes expression in the mouse retina. PLoS One 2014; 9: e106819
• 50 Gianesini C, Hiragaki S, Laurent V. et al. Cone viability is affected by disruption of melatonin receptors signaling. Investig Opthalmology Vis Sci 2016; 57: 94
• 51 Beker MC, Caglayan B, Caglayan AB. et al. Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. Sci Rep 2019; 9: 19082
• 52 Shu T, Wu T, Pang M. et al. Effects and mechanisms of melatonin on neural differentiation of induced pluripotent stem cells. Biochem Biophys Res Commun 2016; 474: 566-571
• 53 Wang X, Sirianni A, Pei Z. et al. The melatonin MT1 receptor axis modulates mutant huntingtin-mediated toxicity. J Neurosci 2011; 31: 14496-14507
• 54 Wu H, Song C, Zhang J. et al. Melatonin-mediated upregulation of GLUT1 blocks exit from pluripotency by increasing the uptake of oxidized vitamin C in mouse embryonic stem cells. FASEB J 2017; 31: 1731-1743
• 55 Parada E, Buendia I, León R. et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. J Pineal Res 2014; 56: 204-212
• 56 Ding K, Wang H, Xu J. et al. Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2–ARE signaling pathway as a potential mechanism. Free Radic Biol Med 2014; 73: 1-11
• 57 Buendia I, Gómez-Rangel V, González-Lafuente L. et al. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology 2015; 99: 187-195
• 58 Mortezaee K, Najafi M, Farhood B. et al. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: an updated review. Life Sci 2019; 228: 228-241
• 59 Duan W, Yang Y, Yi W. et al. New role of JAK2/STAT3 signaling in endothelial cell oxidative stress injury and protective effect of melatonin. PLoS One 2013; 8: e57941
• 60 Hardeland R. Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment. Aging Dis 2012; 3: 194-225
• 61 Mayo JC, Sainz RM, González Menéndez P. et al. Melatonin and sirtuins: a “not-so unexpected” relationship. J Pineal Res 2017; 62: e12391
• 62 Guo P, Pi H, Xu S. et al. Melatonin improves mitochondrial function by promoting MT1/SIRT1/PGC-1 alpha-dependent mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro. Toxicol Sci 2014; 142: 182-195
• 63 Kunst S, Wolloscheck T, Kelleher DK. et al. Pgc-1α and Nr4a1 are target genes of circadian melatonin and dopamine release in murine retina. Investig Opthalmol Vis Sci 2015; 56: 6084
• 64 Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D. et al. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J Pineal Res 2009; 47: 228-237
• 65 Gbahou F, Cecon E, Viault G. et al. Design and validation of the first cell-impermeant melatonin receptor agonist: cell-impermeant melatonin receptor agonist. Br J Pharmacol 2017; 174: 2409-2421
• 66 Hill SM, Belancio VP, Dauchy RT. et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015; 22: R183-R204
• 67 Koziróg M, Poliwczak AR, Duchnowicz P. et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome: melatonin in metabolic syndrome. J Pineal Res 2011; 50: 261-266
• 68 Borghi C, Cicero AFG. Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses: antihypertensive nutraceuticals. Br J Clin Pharmacol 2017; 83: 163-171
• 69 Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: an adjunct anti-hypertensive agent. Clin Exp Pharmacol Physiol 2018; 45: 755-766
• 70 Nduhirabandi F, Maarman G. Melatonin in heart failure: a promising therapeutic strategy?. Molecules 2018; 23: 1819
• 71 Liu Z, Ran Y, Qie S. et al. Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway. CNS Neurosci Ther 2019; 25: 1353-1362
• 72 Lin L, Huang Q-X, Yang S-S. et al. Melatonin in Alzheimer’s disease. Int J Mol Sci 2013; 14: 14575-14593
• 73 Yildirim FB, Ozsoy O, Tanriover G. et al. Mechanism of the beneficial effect of melatonin in experimental Parkinson’s disease. Neurochem Int 2014; 79: 1-11
• 74 Banach M, Gurdziel E, Jędrych M, Borowicz KK. Melatonin in experimental seizures and epilepsy. Pharmacol Rep 2011; 63: 1-11
• 75 Fallah R, Shoroki F, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf 2015; 10: 132-135
• 76 Danilov AB, Danilov AB, Kurushina OV. et al. Safety and efficacy of melatonin in chronic tension-type headache: a post-marketing real-world surveillance program. Pain Ther 2020; 9: 741-750
• 77 Grima NA, Rajaratnam SMW, Mansfield D. et al. Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial. BMC Med 2018; 16: 8
• 78 Tavukçu HH, Şener TE, Tinay İ. et al. Melatonin and tadalafil treatment improves erectile dysfunction after spinal cord injury in rats. Clin Exp Pharmacol Physiol 2014; 41: 309-316
• 79 Hu K-L, Ye X, Wang S, Zhang D. Melatonin application in assisted reproductive technology: a systematic review and meta-analysis of randomized trials. Front Endocrinol 2020; 11: 160
• 80 Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. BMC Gastroenterol 2010; 10: 7
• 81 Chojnacki C, Walecka-Kapica E, Lokieć K. et al. Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women. Endokrynol Pol 2013; 64: 114-120
• 82 Bahrami M, Cheraghpour M, Jafarirad S. et al. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. Complement Ther Med 2020; 52: 102452
• 83 Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. World J Gastroenterol 2010; 16: 6087
• 84 Kim JW, Jo J, Kim J-Y. et al. Melatonin attenuates cisplatin-induced acute kidney injury through dual suppression of apoptosis and necroptosis. Biology 2019; 8: 64
• 85 Dai W, Huang H, Si L. et al. Melatonin prevents sepsis-induced renal injury via the PINK1/Parkin1 signaling pathway. Int J Mol Med 2019; 44: 1197-1204
• 86 Rusanova I, Martínez-Ruiz L, Florido J. et al. Protective effects of melatonin on the skin: future perspectives. Int J Mol Sci 2019; 20: 4948
• 87 Danilov A, Kurganova J. Melatonin in chronic pain syndromes. Pain Ther 2016; 5: 1-17
• 88 Maras A, Schroder CM, Malow BA. et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol 2018; 28: 699-710
• 89 Serfaty MA, Osborne D, Buszewicz MJ. et al. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. Int Clin Psychopharmacol 2010; 25: 132-142
• 90 González-González A, Mediavilla M, Sánchez-Barceló E. Melatonin: A molecule for reducing breast cancer risk. Molecules 2018; 23: 336
• 91 Wang N, Li H, Zhu Y. et al. Melatonin protects against epirubicin-induced ovarian damage. J Reprod Dev 2020; 66: 19-27
• 92 Tahamtan R, Shabestani Monfared A, Tahamtani Y. et al. Radioprotective effect of melatonin on radiation-induced lung injury and lipid peroxidation in rats. Cell J 2015; 17: 111-120
• 93 Wang J, Guo W, Chen W. et al. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. J Pineal Res 2013; 54: 406-416
• 94 Huang S-H, Cao X-J, Liu W. et al. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. J Pineal Res 2010; 48: 109-116
• 95 Ouyang H, Zhong J, Lu J. et al. Inhibitory effect of melatonin on Mst1 ameliorates myocarditis through attenuating ER stress and mitochondrial dysfunction. J Mol Histol 2019; 50: 405-415
• 96 Montiel M, Bonilla E, Valero N. et al. Melatonin decreases brain apoptosis, oxidative stress, and CD200 expression and increased survival rate in mice infected by Venezuelan equine encephalitis virus. Antivir Chem Chemother 2015; 24: 99-108
• 97 Boga JA, Coto-Montes A, Rosales-Corral SA. et al. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”?: melatonin and viral infections. Rev Med Virol 2012; 22: 323-338
• 98 Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J. et al. Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Mult Scler Relat Disord 2022; 58: 103520
• 99 Cross KM, Landis DM, Sehgal L, Payne JD. Melatonin for the early treatment of COVID-19: a Narrative review of current evidence and possible efficacy. Endocr Pract 2021; 27: 850-855
• 100 https://www.authorea.com/users/633263/articles/651744-revealingmelatonin-s-mysteries-receptors-signaling-pathways-andtherapeutics-applications